Higher 104,00 €	Lower 100,00 €
Open 103,00 €	Previous close 103,60 €
Volume142 921	Traded value 14 560 936,40 €
Capitalisation / nb of shares 8 016 991 926 € / 78 444 148	Capital turnover 0,18 %
Sector Industrie Pharmaceutique et Biotechnologie	main indices SBF 120, CAC ALL-TRADABLE
Market Euronext PARIS	Eligible (France): PEA SRD

Annonce

Stock price movement

16/01/2026 à 17:39:20

Technical analysis ABIVAX

50-day moving average103,23 €	Pivot 102,07 €
Support 93,30 € -8.71 %	Résistance 122,40 € +19.77 %
1-month volatility 25,01 %	Annualized volatility 197,30 %
RSI (14d)Neutral (33)	Stochastic signal (14d) Neutre
ATR (14d)High volatility (4,27)	CMF (21d)Mildly bearish (-0,28)
Bollinger (20d)Neutral	OBV (21d) OBV data unavailable

Performance history

Since January 1st, the share price of ABIVAX has fallen by -15,12%. Over three years, the stock has gained 1 371,00%. Over the past 12 months, ABIVAX has recorded a decrease of -15.12%. In the medium term, the stock has shown a decline of -15.12% over the last three months. The share has been slightly volatile over the past rolling quarter. Considering the same periods, ABIVAX has fluctuated by as much as % over the last three months and % over the past twelve months.

Please note: these indicators are for informational purposes only and do not guarantee future results. Past performance is not indicative of future performance.

Share price performance of ABIVAX over various periods:

	Perf	Higher	Lower
1 week	+3,0%	132,00	96,00
1 month	-1,9%	132,00	92,40
3 months	+23,43%	132,00	75,70
6 months	+1 190,00%	132,00	7,98
12 months	+1 551,00%	132,00	4,51
3 years	+1 371,00%	132,00	4,51
5 years	+214,50%	132,00	4,51
Since IPO	+386,70%	132,00	3,87

The information provided in this document is for informational purposes only and should not be considered investment advice. Past performance is no guarantee of future returns. This product carries a risk of capital loss.

Relatited articles about ABIVAX

News

15/01	Abivax Rises 4.63% Midday, Driven by Target Revisions Following Acquisition Speculation
14/01	Abivax Climbs 2.69% on Wednesday, Boosted by Target Revisions and Acquisition Rumors
12/01	Abivax Shares Surge 27% at the Opening of the Paris Stock Exchange
08/01	Abivax Anticipates Phase 3 Trial Results by End of June 2026
08/01	Abivax Targets End of 2026 for Regulatory Filing of Ulcerative Colitis Treatment
03/01	ABIVAX Stock: Shares Fall 5.74% Over the Past Week
31/12	Abivax Shares Climb 2.41% at Midday this Tuesday, December 31
29/12	Abivax Shares Continue to Soar Mid-Day: +4.59% at 127.60 Euros
29/12	Abivax Shares Close at 122.40 Euros, Slightly Down After Annual Surge
27/12	ABIVAX Stock: Shares Gain 22% Over the Week in a Declining Paris Market
22/12	Abivax Shares: +9.4% at Opening, Boosted by Acquisition Rumors by Eli Lilly
22/12	Abivax Shares Soar 15.4% at Close Amid Acquisition Rumors by Eli Lilly
19/12	Abivax Joins the Nasdaq Biotechnology Index
19/12	Abivax Shares Jump 7.17% Midday, Supported by Entry into Nasdaq Biotechnology Index
18/12	Abivax Presents 22 Studies on Obefazimod at the ECCO 2026 Congress
18/12	Abivax Shares Rise Midday After a Flurry of Target Revisions
16/12	Abivax Reports Cash Reserves of 589.7 Million Euros as of September 30, 2025
16/12	Abivax Shares Dip Despite Strong Annual Performance Amid Speculative Fluctuations
16/12	Abivax Shares Drop 9% at Close Following Q3 Results Announcement
10/12	Abivax Shares Soar 15% Mid-Session After a 1,414% Annual Surge

Industry data

Sector	CAC40 performance (%)	Euronext performance (%)

Health Care	-2.55%	-1.26%

Pharmaceuticals & Biotechnology	-1.04%	+0.07%

Biotechnology	N/A	-0.17%

Indice	Pts	Performance (%)

SBF 120	6246.07	-0.65%


NEXT 150	3602.19	-0.01%





NEXT BIOTECH	3412.88	+0.99%

SBF 120 data

Name	Price (€)	Perf.(%)
Best-performing stocks
Least-performing stocks

WARNINGS: The information presented here is based on data published by third-party information providers. It is not contractual and carries no guarantee of accuracy. It should not be considered as investment advice. Ideal-investisseur.fr cannot be held responsible for any potential damages or losses arising from the use of this information.

Stock ABIVAX FR0012333284

Stock data: ABIVAX